Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune Thrombocytopenia: Open-Label, Phase 3 Study

Hiroki Yamaguchi, Masaki Iino, Yutaka Imamura, Shugo Kowata, Ryusuke Yamamoto, Jun Yamanouchi, Masato Fujii, Jessica Zhang, Yoshiaki Tomiyama, Brian Jamieson

Blood (2024) 144 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2024-205479

Published: 2024

Journal Articles

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Masataka Kuwana, Tomoki Ito, Shugo Kowata, Yoshihiro Hatta, Katsumichi Fujimaki, Kensuke Naito, Shingo Kurahashi, Toshiya Kagoo, Kazuki Tanimoto, Natsuko Shichiri, So Saotome, Esteban Masuda, Yoshiaki Tomiyama

Blood (2023) 142 (Supplement 1): 2578.

https://doi.org/10.1182/blood-2023-182113

Published: 2023

Journal Articles

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Blood (2022) 140 (Supplement 1): 11244–11245.

https://doi.org/10.1182/blood-2022-169782

Published: 2022

Journal Articles

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

Blood (2021) 138 (Supplement 1): 1477.

https://doi.org/10.1182/blood-2021-145483

Published: 2021

Journal Articles

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Daigo Michimata, MD, Kazunori Murai, MD PhD, Yasuro Miyairi, MD, PhD, Yoshiaki Okano, MD, PhD, Yuuzou Suzuki, MD, PhD, Hiroyuki Hamada, MD, Akiyoshi Sato, MD, PhD, Tatsuo Oyake, Shugo Kowata, MD, PhD, Yasuhiko Tsukushi, MD, PhD, Norifumi Sugawara, MD, PhD, Akihiro Otsu, MD, PhD, Kenji Shimosegawa, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2019) 134 (Supplement_1): 2928.

https://doi.org/10.1182/blood-2019-125066

Published: 2019

Journal Articles

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, Norifumi Sugawara, MD, PhD, Shinri Miyajima, MD, Kazuki Kiyohara, MD, Maki Nishiya, MD PhD, Tadashi Shimoyama, MD PhD, Yuka Takemasa-Fujisawa, MD PhD, Ryosei Sasaki, MD PhD, Wataru Izumita, MD, Yasuhiko Tsukushi, MD, PhD, Akihiro Otsu, MD, PhD, Takahiro Mine, MD, Takeshi Sugawara, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, PhD, Ichiro Hanamura, MD PhD, Shugo Kowata, MD, PhD, Shigeki Ito, MD, PhD

Blood (2019) 134 (Supplement_1): 4865.

https://doi.org/10.1182/blood-2019-131305

Published: 2019

Journal Articles

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Blood (2016) 128 (22): 3102.

https://doi.org/10.1182/blood.V128.22.3102.3102

Published: 2016

Journal Articles

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Ryousei Sasaki, MD, PhD, Wataru Izumita, MD, Takahiro Mine, MD, Maki Asahi, MD, PhD, Yuzo Suzuki, MD, PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yasuhiko Tsukushi, MD, PhD, Yusei Aoki, MD, Shugo Kowata, MD, PhD, Ichiro Hanamura, MD, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2016) 128 (22): 1607.

https://doi.org/10.1182/blood.V128.22.1607.1607

Published: 2016

Journal Articles

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Tatsuo Oyake, MD PhD, Takayuki Masuda, MD PhD, Norifumi Sugawara, MD PhD, Maki Asahi, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD PhD, Shigeki Ito, MD PhD, Yoji Ishida, MDPhD

Blood (2015) 126 (23): 4621.

https://doi.org/10.1182/blood.V126.23.4621.4621

Published: 2015

Journal Articles

Platelet Progenitors after Leaving Bone Marrow

Shugo Kowata, MD PhD, Ryo Togawa, MD, Yoshiaki Okano, MD, Sumio Isogai, PhD, Jiro Hitomi, MDPhD, Kazunori Murai, MDPhD, Shigeki Ito, MD PhD, Yoji Ishida, MD, PhD

Blood (2015) 126 (23): 2249.

https://doi.org/10.1182/blood.V126.23.2249.2249

Published: 2015

Journal Articles

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Kazunori Murai, PhD MD, Shigeki Ito, MD PhD, Shugo Kowata, MD, Tatsuo Oyake, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4560.

https://doi.org/10.1182/blood.V124.21.4560.4560

Published: 2014

Journal Articles

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Yasunori Nakagawa, MD, PhD, Takahiro Mine, MD, Ichiro Hanamura, MD, PhD, Maki Asahi, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4954.

https://doi.org/10.1182/blood.V124.21.4954.4954

Published: 2014

Journal Articles

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Tadashi Shimoyama, MD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 1456.

https://doi.org/10.1182/blood.V124.21.1456.1456

Published: 2014

Journal Articles

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Yukiteru Fujishima, MD, Yasuhiko Tsukushi, M.D., Takahiro Mine, MD., Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1071.

https://doi.org/10.1182/blood.V122.21.1071.1071

Published: 2013

Journal Articles

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Tatsuo Oyake, M.D., Ph.D., Tadashi Shimoyama, Maki Asahi, Sugawara Norifumi, Ryosei Sasaki, Suzuki Yuzo, Fujishima Yukiteru, Yasuhiko Tsukushi, M.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2186.

https://doi.org/10.1182/blood.V120.21.2186.2186

Published: 2012

Journal Articles

Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.

Shugo Kowata, MD., Sumio Isogai, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Koujiro Tohyama, PhD, Jiro Hitomi, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2300.

https://doi.org/10.1182/blood.V120.21.2300.2300

Published: 2012

Journal Articles

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2011) 118 (21): 2228.

https://doi.org/10.1182/blood.V118.21.2228.2228

Published: 2011

Journal Articles

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, MD, PhD, Kenichi Nomura, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 3696.

https://doi.org/10.1182/blood.V116.21.3696.3696

Published: 2010

Journal Articles

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Tomoaki Akagi, MD, PhD, Koumei Kubo, MD, PhD, Kenichi Sawada, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 1062.

https://doi.org/10.1182/blood.V116.21.1062.1062

Published: 2010

Journal Articles

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Shugo Kowata, MD, Kazunori Murai, MD, PhD, Kenichi Nomura, MD, PhD, Tatsuo Oyake, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 4793.

https://doi.org/10.1182/blood.V116.21.4793.4793

Published: 2010

NARROW

Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune Thrombocytopenia: Open-Label, Phase 3 Study

Long-Term Treatment with Fostamatinib in Japanese Patients with Primary Immune Thrombocytopenia: An Open-Label Extension Study Following a Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group Study

Fostamatinib for the Treatment of Japanese Patients with Primary Immune Thrombocytopenia: A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group Study

Importance of the Duration of TKI Treatment in Treatment-Free Remission of Chronic Phase Chronic Myeloid Leukemia: Results of D-Free Trial

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Platelet Progenitors after Leaving Bone Marrow

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only